Denosumab (PROLIA) ELISA Assay Kit

$1,375.00

The Denosumab (PROLIA) ELISA Assay Kit has been developed for the quantitative determination of denosumab in serum and plasma samples between the Cmin and Cmax range of concentrations. The Denosumab (PROLIA) ELISA Assay Kit is for research use only and not to be used for diagnostic procedures.

SKU: DEN-FD-PRO Categories: , , Tag:

Denosumab (PROLIA) ELISA Assay Kit

The Denosumab (PROLIA) ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: 10 ng/mL
Standard Range: 0 – 300 ng/mL
Incubation Time: 1 hour 10 minutes
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Name: Prolia


Assay Background

Denosumab is a novel, fully human lgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intra molecular disulphides. Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. In many bone losses, RANKL overwhelms the body’s natural defense against bone destruction. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RAN KL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.

Assay Principle

Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for denosumab. After incubation the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to denosumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The colour developed is proportional to the amount of denosumab in the sample or standard. Results of samples can be determined directly using the standard curve.


Related Products

Anti-Denosumab ELISA Assay
Atezolizumab (Tecentriq) ELISA Kit
Daratumumab Darzalex ELISA

Package Inserts


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations